Printer Friendly

ANOTHER FIRST FOR GAMMA BIOLOGICALS; COMPANY RECEIVES FIRST EVER LICENSE FOR MONOCLONAL COOMBS REAGENTS

      ANOTHER FIRST FOR GAMMA BIOLOGICALS; COMPANY RECEIVES
        FIRST EVER LICENSE FOR MONOCLONAL COOMBS REAGENTS
    HOUSTON, March 2 /PRNewswire/ -- Gamma Biologicals, Inc. (AMEX: GBL), has received the first license ever issued by the Food and Drug Administration for four antihuman globulin (Coombs) reagents manufactured totally from monoclonal antibodies.  The Coombs test is one of the most widely performed procedures in clinical medicine, and these reagent products are used routinely in the testing of all blood donors and obstetrical and presurgery patients.
    Chairman and President David E. Hatcher said, "This new line of superior products will have a positive effect on the company's revenues and earnings during the coming quarters."
    Antihuman globulin reagents are the company's largest dollar sales product line.  Gamma obtained the first U.S. license for a monoclonal blood grouping reagent and is the company with the most (14) such products.
    Gamma completed field testing on the monoclonal Coombs reagents and filed with the FDA in November 1990.  Because of FDA budget limitations, the review process took longer than the normal six months.
    Gamma owns the clones for the total Coombs line and cultures the raw materials in-house, which guarantees supply and substantially reduces cost.
    Since 1945, the Coombs reagent source has been immunized rabbit blood serum.  The newly approved monoclonal reagents will allow the company to retire its rabbit colony within two years.
    Gamma Biologicals manufactures and markets a wide range of highly refined and specialized testing products, known as diagnostic reagents, as well as specialized instrument systems.  The company markets to hospitals, blood banks, medical laboratories, physicians' offices and research institutions.
    -0-                       3/2/92
    /CONTACT:  David E. Hatcher, chairman and president, or John J. Moulds, executive vice president of Gamma Biologicals, 713-681-8481/
    (GBL) CO:  Gamma Biologicals Inc. ST:  Texas IN:  MTC SU : SM -- NY030 -- 3856 03/02/92 10:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 2, 1992
Words:305
Previous Article:CALIFORNIA UNITES IN FIGHT AGAINST H.R. 1790
Next Article:GULL LABORATORIES AND BAXTER INTERNATIONAL ENTER MANUFACTURING/DISTRIBUTION AGREEMENT
Topics:


Related Articles
FINAL CASH SETTLEMENT ON ITALIAN SALE TO FUND BIOELECTRICAL SENSOR TECHNOLOGY DEVELOPMENT FOR GAMMA BIOLOGICALS
GAMMA BIOLOGICALS NAMES JOHN J. MOULDS PRESIDENT
GAMMA BIOLOGICALS REVIEWS ELECTRO-BIOSENSOR PROJECT; TESTS CONFIRM PROJECT FEASIBILITY; DEVELOPMENT TO CONTINUE
GAMMA BIOLOGICALS REPORTS STRONG EARNINGS FOR QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 1993
GAMMA BIOLOGICALS REPORTS EARNINGS FOR FIRST QUARTER ENDED JUNE 30, 1994
GAMMA BIOLOGICALS ANNOUNCES DIVIDEND
GAMMA BIOLOGICALS REPORTS EARNINGS FOR SECOND QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 1995
GAMMA BIOLOGICALS ANNOUNCES JANUARY DIVIDEND
GAMMA BIOLOGICALS REPORTS EARNINGS FOR THIRD QUARTER AND NINE MONTHS ENDED DEC. 31, 1995
Gamma Biologicals Reports Earnings for the Third Quarter and Nine Months Ended December 31, 1996

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters